Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1169 details
Primary information
ID1705
ThPP IDTh1169
Therapeutic Peptide/Protein NameBeractant
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life20–30 h.
DescriptionBeractant is a pulmonary surfactant made from natural bovine lung extract.
Indication/DiseaseBeractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants.
PharmacodynamicsEndogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants.
Mechanism of ActionIt reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance.
ToxicityNA
MetabolismSurfactant is recycled and metabolized exclusively in the lungs.
AbsorptionAbsorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement.
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionBretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant.
TargetNA
Information of corresponding available drug in the market
Brand NameNA
CompanyNA
Brand DiscriptionNA
Prescribed forNA
Chemical NameNA
FormulationNA
Physcial AppearanceNA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side Effectspale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube.
Useful Linkhttp://www.rxlist.com/survanta-drug/clinical-pharmacology.htm; http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/B018.html
PubMed ID17533176, 15813666
3-D StructureN.A.
Primary information
ID1706
ThPP IDTh1169
Therapeutic Peptide/Protein NameBeractant
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life20–30 h.
DescriptionBeractant is a pulmonary surfactant made from natural bovine lung extract.
Indication/DiseaseBeractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants.
PharmacodynamicsEndogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants.
Mechanism of ActionIn vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.
ToxicityNA
MetabolismSurfactant is recycled and metabolized exclusively in the lungs.
AbsorptionAbsorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement.
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionBretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant.
TargetNA
Information of corresponding available drug in the market
Brand NameSurvanta
CompanyAbb Vie Inc.
Brand DiscriptionSURVANTA ® (beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant.
Prescribed forSURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.
Chemical NameNA
Formulation25 mg/mL
Physcial AppearanceSuspension
Route of Administrationendotracheal
Recommended DosageEach dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg).
ContraindicationNA
Side Effectspale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube.
Useful Link
PubMed ID17533176, 15813666
3-D StructureN.A.
Primary information
ID1707
ThPP IDTh1169
Therapeutic Peptide/Protein NameBeractant
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life20–30 h.
DescriptionBeractant is a pulmonary surfactant made from natural bovine lung extract.
Indication/DiseaseBeractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants.
PharmacodynamicsEndogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants.
Mechanism of ActionIn vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.
ToxicityNA
MetabolismSurfactant is recycled and metabolized exclusively in the lungs.
AbsorptionAbsorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement.
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionBretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant.
TargetNA
Information of corresponding available drug in the market
Brand NameSurvanta
CompanyAbbvie Corporation
Brand DiscriptionSURVANTA ® (beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant.
Prescribed forSURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.
Chemical NameNA
Formulation25 mg
Physcial AppearanceSuspension
Route of Administrationintratracheal
Recommended DosageEach dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg).
ContraindicationNA
Side Effectspale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube.
Useful Link
PubMed ID17533176, 15813666
3-D StructureN.A.